Back to top
more

Avadel Pharmaceuticals (AVDL)

(Delayed Data from NSDQ)

$18.09 USD

18.09
985,700

+1.13 (6.63%)

Updated Apr 23, 2024 03:59 PM ET

After-Market: $18.07 -0.02 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Invest in Avadel (AVDL) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.

Avadel (AVDL) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

How Much Upside is Left in Avadel (AVDL)? Wall Street Analysts Think 37.36%

by Zacks Equity Research

The consensus price target hints at a 37.4% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Why Avadel Pharmaceuticals (AVDL) Stock Might be a Great Pick

by Zacks Equity Research

Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?

by Zacks Equity Research

Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.

Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 105.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Do Options Traders Know Something About Avadel (AVDL) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

Implied Volatility Surging for Avadel (AVDL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.

Avadel (AVDL) Surges: Stock Moves 7.8% Higher

by Zacks Equity Research

Avadel (AVDL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

How Avadel (AVDL) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Avadel (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Avadel (AVDL) Beats on Earnings & Revenue Estimates in Q1

by Zacks Equity Research

Avadel's (AVDL) first quarter 2020 earnings and revenues surpass expectations.

Is a Beat in Store for Avadel (AVDL) This Earnings Season?

by Zacks Equity Research

On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.

Avadel's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.

Is Avadel Pharmaceuticals (AVDL) Stock a Solid Choice Right Now?

by Zacks Equity Research

Avadel Pharmaceuticals (AVDL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Implied Volatility Surging for Avadel Pharmaceuticals (AVDL) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.

Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

by Zacks Equity Research

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

Avadel (AVDL) Is Up 21.13% in One Week: What You Should Know

by Zacks Equity Research

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Sanghamitra Saha headshot

5 Top-Ranked ADRs That More Than Doubled the S&P 500 in 2019

by Sanghamitra Saha

Though international markets trailed the U.S. market in 2019, there are hidden gems that crushed the S&P 500 this year on stock-specific strength.

Avadel (AVDL) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Avadel (AVDL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Top Ranked Momentum Stocks to Buy for December 9th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 9th

Will Avadel Pharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.

Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe

by Zacks Equity Research

Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.